Sign In
Buy SDGR
$15.14
-0.210 (-1.37%)
At Close: Jul 31, 2026
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:30am, Thursday, 18'th Sep 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 14, 2025, the company granted restricted stock units (RSUs) with respect to 1,666 shares of the company's
Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?
10:55am, Tuesday, 09'th Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the po
Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
03:05pm, Monday, 08'th Sep 2025
Schrödinger, Inc. (NASDAQ:SDGR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Ramy Farid - CEO, President & Director Karen Akinsanya - P
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
08:30am, Wednesday, 27'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The liv
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 15'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's com
Schrödinger Announces Discontinuation of SGR-2921 Program
07:00am, Thursday, 14'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Ph
Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript
09:20pm, Wednesday, 06'th Aug 2025
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Kare
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates
07:32pm, Wednesday, 06'th Aug 2025
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.74 per share a year ago.
Schrödinger (SDGR) Q2 2025 Earnings Transcript
05:28pm, Wednesday, 06'th Aug 2025
Image source: The Motley Fool.
Schrödinger Reports Second Quarter 2025 Financial Results
04:05pm, Wednesday, 06'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6
08:30am, Friday, 25'th Jul 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a co
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:06am, Wednesday, 23'rd Jul 2025
Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Material Informatics Companies Quadrant presents an in-depth analysis of the global material informatics market. This industry review highlights leading companies, technological advancements, and
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 18'th Jul 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 14, 2025, the company granted restricted stock units (RSUs) with respect to 3,488 shares of the company's commo
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target
08:00am, Thursday, 17'th Jul 2025
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janu
